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Join us at The Lancet Clinic
On Oct 5, 2015, we launch the ﬁ rst 45 disease-speciﬁ c 
pages of a major new online initiative involving all Lancet 
journals that will bring together an overview Seminar 
and relevant Reviews, Clinical Series, Commissions, 
research, Case Reports, and Clinical Pictures. Over the 
next 18 months or so when The Lancet Clinic is complete, 
there will be online pages for 135 diseases, which we have 
identiﬁ ed by a combination of global burden of disease 
data and clinical practice needs. We hope that The Lancet 
Clinic will help practising doctors make better informed 
decisions that ultimately lead to better lives of people 
worldwide, and help others who want to educate or 
update themselves keep abreast of the evolving evidence 
base. Importantly, these pages will be updated at regular 
intervals. The authors of newly commissioned Seminars 
have agreed to provide regular summaries of important 
new evidence for 4 years. Individual clinical editors will pull 
together newly published material from across the Lancet 
journals and post links to these on the page regularly.
In addition, we are continuing our regular editorial 
policies of commissioning more specialised Clinical 
Reviews and Series across The Lancet Group to provide a 
more focused and in-depth assessment for key diseases. 
And beyond providing knowledge and information, we 
want to encourage academic and practising clinicians 
to use this knowledge for advocacy and change. In 
2014, The Lancet published the ﬁ rst Clinical Commission 
on liver disease in the UK and in February, 2015, we 
launched our ﬁ rst Clinical Campaign based on this 
Commission. A Cancer Campaign as a joint eﬀ ort 
between The Lancet and The Lancet Oncology followed 
in April. Clinical Campaigns aim to eﬀ ect change based 
on data, knowledge, and expert interpretation in 
partnership with others. Further Clinical Commissions on 
asthma, hypertension, dementia, tuberculosis, traumatic 
brain injury, psychotherapy, chronic obstructive 
pulmonary disease, and others are underway across all 
Lancet journals. With these Clinical Commissions and 
Campaigns, we hope to extend our goal to publish the 
best science for better lives to being an active partner in 
using this science for actual change. Commissions and 
Campaigns will be part of the disease pages to encourage 
engagement and actions. The Lancet Clinic invites you to 
be part of this endeavour.
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